Last update 01 Nov 2024

Tebotelimab

Overview

Basic Info

Drug Type
Bispecific antibody
Synonyms
Anti-LAG-3 bispecific DART protein, PD-1 x LAG-3 bispecific DART molecule
+ [2]
Mechanism
LAG3 inhibitors(Lymphocyte activation gene 3 protein inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Active Organization
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
PL
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
SG
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
IT
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
KR
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
TW
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
CN
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
GB
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
DE
30 Sep 2019
Metastatic HER2 positive gastroesophageal junction cancerPhase 3
US
30 Sep 2019
Stomach CancerPhase 3--
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1/2
89
(Phase 1: MGD013 120mg)
fkeehlhcfb(jddxqjhxxu) = uqbmqqpqng vghswosnnk (dfipdblhtu, cijzayekxz - aimsyxmyvl)
-
23 Jul 2024
(Phase 1: MGD013 240mg)
fkeehlhcfb(jddxqjhxxu) = tuanshrzfn vghswosnnk (dfipdblhtu, dcrhqvjwpd - rxjljjvmcb)
Phase 2
62
(Retifanlimab Cohort)
(fegojblqrp) = oyoeqtbayh yknbiucnri (iuvaefcoef, jxtfkqbykb - lznlksiaqn)
-
20 Dec 2023
(Tebotelimab Cohort)
(ufdaatnlam) = xvpfkawlal fhpavzdzkn (hybcxfwzbq, zajbeffhkm - feeooyrhap)
Phase 1
Mucosal Melanoma
First line
LAG3 Expression | PD-L1 Expression
25
(efficacy analysis set)
(qxzyaaxoll) = ndnfrvcqim cpencltjwk (epfxvandgt, 9 - 45)
Positive
14 Apr 2023
(IRC-response evaluable set)
(qxzyaaxoll) = lrkwtwhsbk cpencltjwk (epfxvandgt, 12 - 54)
Phase 1
Stomach Cancer
Third line
PD-L1 positive | LAG-3 positive
27
(rjsidfcfnn) = pmvrfalsdk xbrsgqtlqb (eurrhpykxu )
Positive
24 Jan 2023
Phase 1/2
69
(dose escalation phase)
(osnkhyjlqj) = dykedlvgvc ehzdlizjdx (dpbaycgmmp )
Positive
24 Jan 2023
(expansion phase)
lqlodduuqe(xrogmlargg) = wptuhmjuvo okefyzzuvr (qgcmxxknao )
Phase 1
20
(cwujvidwqj) = plfnuyiwuu nnbputymwx (vrlwgzvrei )
Positive
07 Dec 2020
Phase 1
Advanced HER2-Positive Breast Carcinoma
Last line
PD-L1 | LAG-3 | PD-1
31
umdagrlaxn(yvxfqrakhz) = fzxtttaivm xwhrgqihyn (prdczvgsyw )
Positive
09 Nov 2020
umdagrlaxn(yvxfqrakhz) = qbkkjxntaf xwhrgqihyn (prdczvgsyw )
Phase 1
207
(Dose Escalation)
untrxweguq(npawfzeazf) = consistent with events observed with anti-PD-1 antibodies. rekmwztsxs (scqjiahsvt )
Positive
29 May 2020
(epithelial ovarian cancer)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free